ABSTRACT
INTRODUCTION
Hemorrhagic transformation (HT) is a common complication of intra-arterial thrombolysis for the treatment of acute ischemic stroke, with an estimated incidence rate of 18-71% [1, 2] , depending on factors such as the thrombolytic agent used and the route of administration [1, 3, 4] . Recent studies showed that different s ubtypes of HT may have a different prognosis, some having a higher recanalization rate and better outcome [5] ,while some are associated with very poor clinical outcomes [6] . So far, a diverse set of predisposing factors for the occurrence of HT has been identifi ed, including a decreased level of total cholesterol [7] , poor collateral circulation [2] , a high National Institutes of Health Stroke Scale (NIHSS) score, a low platelet count, and a high glucose level [3] , but t he independent clinical 
METHODS Participants
We performed a retrospective study in patients receiving intra-arterial thrombolysis. Intra-arterial thrombolysis was considered when a patient presented with acute cerebral 
Thrombolytic Procedure
Cerebral angiography was performed using a transfemoral approach. A diagnostic angiogram was used to determine the target vessels, and the t hrombolytic agent (urokinase up to a total dose of 1 250 000 IU, or recombinant tissue plasminogen activator (rt-PA) up to a total dose of 20 mg) was delivered through a m icrocatheter. A small dose of thrombolytic agent was delivered distal to the thrombus. Then the catheter was retracted into the proximal thrombus, where a small dose of t hrombolytic agent was injected. After that, a large dose was infused proximal to the occlusion. Mechanical thrombus disruption was performed during the operation according to the situation. Diagnostic angiograms were performed at regular intervals to assess recanalization. The thrombolytic agent infusion was discontinued when the following occurred:
(1) adequate revascularization was achieved; (2) partial or no recanalization occurred but the maximal safe dose of thrombolytic agent had been administered; (3) bleeding out of contrast material was noted; and (4) there was suspicion that HT may have occurred [3] .
Defi nition of HT
All CT scans were evaluated by a neuroradiologist blinded to the clinical characteristics of the stroke and its progress toward HT. HT was defined as displaying any degree of hyperdensity within the low attenuation area [7] , including (1) hemorrhagic infarction 1 (HI1): small petechiae along the margins of the infarct; (2) hemorrhagic infarction 2 (HI2):
confluent petechiae within the infarcted area but without a space-occupying effect; (3) parenchymal hemorrhage 1 (PH1): hematoma ≤30% of the infarcted area with some slight space-occupying effect; and (4) parenchymal hemorrhage 2 (PH2): hematoma >30% of the infarcted area with a substantial space-occupying effect according to the European Cooperative Acute Stroke Study classifi cation [8] .
T he patients were divided into HT and non-HT groups.
Symptomatic HT was defined as any type of intracranial hemorrhage on any post-treatment imaging after the start of thrombolysis and NIHSS deterioration of ≥4 from baseline, or from the lowest value within 7 days, or leading to death [9] . and random blood glucose test were conducted. The other predictors were the time-window for intra-arterial thrombolysis, recanalization, NIHSS score, and systolic blood pressure before intra-arterial thrombolysis.
Laboratory Tests and Oth er Predictors

Statistical Analysis
All 
RESULTS
Study Population and Epidemiologic Data
In the 216 patients recruited, the incidence rate of HT was
19.0% (41/216). Among the 41 patients with HT, 15 (36.6%)
were with HI1, 17 (41.5%) with HI2, 6 (14.6%) with PH1, and 3 (7.3%) with PH2; 9 (22.0%) were symptomatic HT and 32 (78.0%) were asymptomatic HT; mortality rate was 19.5% (8/41). The incidence rate of non-HT was 81.0% (175 of 216), and the mortality rate among them was 20% (35 of 175). Other population data are shown in Table 1 .
Risk Factors in HT and Non-HT Groups
We did not fi nd any signifi cant difference in age, sex, history of stroke, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease and atrial fibrillation, smoking, alcohol consumption, antiplatelet and anticoagulant therapies before receiving intra-arterial thrombolysis therapy, thrombolytic agent , time-window for intra-arterial thrombolysis, recanalization, or systolic blood pressure between the HT and non-HT groups. However, the NIHSS score was signifi cantly higher in the HT group than in the non-HT group (z = -3.075, P = 0.002) ( Table 1 ). In addition, the mortality rates in the two groups were similar (t = 0.005, P = 0.944).
The laboratory measurements prior to intra-arterial Patients with a higher globulin or PTA level had a signifi cantly increased risk of developing HT (Table 2) . For the white blood cell count, the difference between groups showed a trend close to signifi cance (P = 0.067) ( Table 2 ).
In the multifactorial logistic regression model, we included globulin level, PTA, white blood cell count, and NIHSS score, and found that all four were signifi cantly increased in the HT group (Table 3 ).
In addition, we did not fi nd any signifi cant difference in age, sex, history of stroke, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease and atrial fi brillation, smoking, alcohol consumption, thrombolytic agent, timewindow for intra-arterial thrombolysis, recanalization, NIHSS score before intra-arterial thrombolysis, systolic blood pressure before intra-arterial thrombolysis, and laboratory tests between the symptomatic HT and asymptomatic HT groups. However, compared to the non-HT group, the globulin level was signifi cantly increased in the HI2, PH1, PH2, and HI2+PH1+PH2 groups, but not in the HI1 group (P = 0.727) ( Table 4) .
DISCUSSION
In the present study, we demonstrated that the incidence rate of HT after intra-arterial thrombolysis was 19%, similar to previous studies [1, 2] . The mortality rates were similar in the HT and non-HT groups, indicating that HT did not increase the risk of death in patients receiving intra-arterial thrombolysis. In addition, using the multifactorial logistic regression model, we found that the globulin level, PTA, white blood cell count, and NIHSS score were signifi cantly increased in the HT group compared with the non-HT group. These results are not completely consistent with previous reports [3] . Notably, we found that the increase in globulin level was an independent risk factor for HT in patients receiving intra-arterial thrombolysis.
Previous studies have indicated that in some patients with acute ischemia, inflammatory cytokines tend to increase, and these patients tend to have a poor prognosis [10] ; however, the underlying pathogenesis of the increased inflammatory cytokines is not well understood [11] [12] [13] .
A recent study has identifi ed six genes that correspond to the differences in inflammation between stroke patients with later development of HT and those without HT [13] .
The differences in genetic regulation of inflammatory processes might explain why some develop a greater inflammatory response than others [10, 13, 14] . The cytokines including interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor α (TNFα) can act on the liver and induce the synthesis of positive acute-phase reactants by the liver mediated by acute-phase protein genes [7, 11, [15] [16] [17] [18] . Most of these are globulins, including C-reactive protein, α 2 -macroglobulin, prothrombin, fi brinogen, and serum amyloid A (among others), and this might explain the increased serum globulin level in our study. Some of these acutephase proteins (prothrombin, fibrinogen, and others) can affect the coagulation mechanism, which may also be related to HT (Fig. 1) .
Simultaneously, some inflammatory cytokines, most importantly IL-1, IL-6, and TNFα, can strongly up-regulate matrix metalloproteinase 9 (MMP-9) [19] [20] [21] [22] , an independent biochemical predictor of HT in all stroke subtypes [23] . A previous study indicated that MMP-9 is involved in tPAassociated hemorrhage, and combination therapy of tPA with MMP inhibitors may help decrease the risk and severity of HT (Fig. 1 ) [24] . Therefore, uncontrolled MMP activation after tPA reperfusion can degrade critical proteins in the cerebrovasculature, thus disrupting vascular structural integrity and eventually leading to rupture of the vessel [24] .
In this study, we assumed that the inflammatory cytokines were more active in the HT group than in the non-HT group due to genetic variation of the infl ammatory system. It appears that MMP-9 could be induced by IL-1, IL-6, and TNFα, resulting in a high incidence of HT. Meanwhile, acute-phase reactants synthesized by the liver were increased, as well as the globulin level. Serum globulin electrophoresis may be useful for predicting HT in patients receiving intra-arterial thrombolysis therapy; however, because of the retrospective design of this study, we were unable to obtain data regarding infl ammatory cytokines in that correspond to differences in inflammation and may be a predictor of HT in ischemic stroke [13] , supporting the hypothesis of an immune infl ammatory response. Notably, we did not fi nd any signifi cant difference in globulin levels between the symptomatic and asymptomatic HT groups, probably due to the small sample size and other unknown mechanisms. We intend to perform future studies focusing on the role of cytokines in HT.
In our single-factor analysis of the risk factors for HT, the P value for the difference in white blood cell count between HT and non-HT groups was 0.067, close to 0.05; thus, we included white blood cell count in the subsequent multifactor logistic regression model. We found that white blood cell count was significantly increased in the HT group. The pathogenesis of the increased white blood cell count in the HT group is not well understood, but it may be associated with the stress response after cerebral infarction or the effect of acute-phase proteins. We were also unable to account for the mechanism underlying the signifi cant difference in PTA between the two groups (even though the OR value was close to 1.0). We suspect the pathogenesis may have some association with acute-phase reactants synthesized by the liver. Some positive acutephase proteins such as fi brinogen, prothrombin, factor VIII, and von Willebrand factor (among others) may influence the coagulation mechanism. We also found that, in the HT group, the NIHSS score before intra-arterial thrombolysis was higher, which was similar to the study by Kidwell et al., who indicated that a higher NIHSS score is an independent predictor of any HT [3] . Further studies are necessary to explore these mechanisms.
D'Amelio et al. indicated that lower levels of total cholesterol and low-density lipoprotein cholesterol are associated with HT [7] , but we did n ot fi nd this association.
The disparity may be due to our inclusion criteria. All of our patients received intra-arterial thrombolysis therapy, but none of the patients in the study by D'Amelio et al. received this therapy. Other previous studies have shown that se rum glucose level is an independent predictor of HT [2, 25] ; controlling serum glucose level may reduce the risk of HT. However, our results did not indicate that serum glucose levels predicted HT, similar to the fi ndings of Kimura et al. [26] .
It also must be emphasized that the use of arterial approved its clinical application [27] . Extrapolation to rt-PA and urokinase, the widely-used intravenous cerebral thrombolytic agents, is based on consensus and case series data [27, 28] . In our study, we did not fi nd any signifi cant relationships of thrombolytic agents in the HT and non-HT groups.
Experts have been trying to find predictors in recent years and some prediction schemes have been produced.
Hallevi et al. proposed the Houston IAT score, which is useful in comparing cohorts of patients and in assessing the results of clinical trials of HT [29] . Our study describes the risk factors for HT in patients receiving intra-arterial thrombolysis using an analysis of routine laboratory data. We found that the increased globulin level was an independent risk factor for HT in patients receiving intra-arterial thrombolysis. Furthermore, we proposed possible explanations for this phenomenon that involve infl ammatory cytokines (IL-1, IL-6, and TNFα), MMP-9, and positive acute-phase reactants synthesized by the liver.
We hope our fi ndings will attract the attention of clinicians to explore the pa thophysiological mechanisms behind HT.
Si nce this is a retrospective study, some limitations such as recall bias and record bias may affect the accuracy of early successful recanalization and better outcome [5] . In our study, we found that globulin level was significantly increased in some subtypes (HI2, PH1, and PH2) compared to the non-HT group. Nevertheless, we have to admit that our sample size is too small. Further studies are necessary to explore predictors for different subtypes of HT.
In conclusion, an increase in globulin level is an independent risk factor for HT in patients receiving intraarterial thrombolysis, with the possible mechanisms involving inflammatory cytokines (IL-1, IL-6, and TNFα), MMP-9, and positive acute-phase reactants synthesized by the liver. Serum globulin electrophoresis may be useful for predicting HT in this population.
